leronlimab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
leronlimab

GtoPdb Ligand ID: 10752

Synonyms: PRO 140 | PRO-140 | PRO140 | Vyrologix®

Compound class: Antibody

Comment: Leronlimab (PRO140) is a humanized anti-CCR5 (C-C motif chemokine receptor 5) monoclonal antibody [5-6]. It was originally developed by CytoDyn as a novel strategy to manage CCR5-tropic HIV infection [4].

SARS-CoV-2 and COVID-19: Leronlimab has been administered to a number of patients with severe COVID-19, to determine its potential to reduce cytokine storm caused by this disease.

References
1. Burger DR, Parker Y, Guinta K, Lindner D. (2018) PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry^null Mice. Biol Blood Marrow Transplant, 24 (2): 260-266. [PMID:29128556]
2. CytoDyn. Press Release April 09, 2020 (Southern California MC). Accessed on 27/04/2020. Modified on 27/04/2020. CytoDyn, https://www.cytodyn.com/newsroom/press-releases/detail/412/severely-ill-covid-19-patient-at-leading-southern
3. CytoDyn. Press release April 09, 2020. Accessed on 27/04/2020. Modified on 27/04/2020. CytoDyn, https://www.cytodyn.com/newsroom/press-releases/detail/413/blood-samples-at-day-0-3-and-7-for-severely-ill-covid-19
4. Dhody K, Pourhassan N, Kazempour K, Green D, Badri S, Mekonnen H, Burger D, Maddon PJ. (2018) PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection. HIV Clin Trials, 19 (3): 85-93. [PMID:29676212]
5. Jiao X, Nawab O, Patel T, Kossenkov AV, Halama N, Jaeger D, Pestell RG. (2019) Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology. Cancer Res, 79 (19): 4801-4807. [PMID:31292161]
6. Miao M, De Clercq E, Li G. (2020) Clinical significance of chemokine receptor antagonists. Expert Opin Drug Metab Toxicol, 16 (1): 11-30. [PMID:31903790]
7. Olson WC, Maddon PJ, Tsurushita N, Hinton PR, Vasquez M. (2006) Anti-CCR5 antibody. Patent number: US7122185B2. Assignee: CytoDyn Inc; AbbVie Biotherapeutics Inc. Priority date: 22/02/2002. Publication date: 17/10/2006.

References

1. Burger DR, Parker Y, Guinta K, Lindner D. (2018)
PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry^null Mice.
Biol Blood Marrow Transplant, 24 (2): 260-266. [PMID:29128556]

2. CytoDyn.
Press Release April 09, 2020 (Southern California MC).
Accessed on 27/04/2020. Modified on 27/04/2020. CytoDyn, https://www.cytodyn.com/newsroom/press-releases/detail/412/severely-ill-covid-19-patient-at-leading-southern

3. CytoDyn.
Press release April 09, 2020.
Accessed on 27/04/2020. Modified on 27/04/2020. CytoDyn, https://www.cytodyn.com/newsroom/press-releases/detail/413/blood-samples-at-day-0-3-and-7-for-severely-ill-covid-19

4. Dhody K, Pourhassan N, Kazempour K, Green D, Badri S, Mekonnen H, Burger D, Maddon PJ. (2018)
PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection.
HIV Clin Trials, 19 (3): 85-93. [PMID:29676212]

5. Jiao X, Nawab O, Patel T, Kossenkov AV, Halama N, Jaeger D, Pestell RG. (2019)
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology.
Cancer Res, 79 (19): 4801-4807. [PMID:31292161]

6. Miao M, De Clercq E, Li G. (2020)
Clinical significance of chemokine receptor antagonists.
Expert Opin Drug Metab Toxicol, 16 (1): 11-30. [PMID:31903790]

7. Olson WC, Maddon PJ, Tsurushita N, Hinton PR, Vasquez M. (2006)
Anti-CCR5 antibody.
Patent number: US7122185B2. Assignee: CytoDyn Inc; AbbVie Biotherapeutics Inc. Priority date: 22/02/2002. Publication date: 17/10/2006.